{
    "ticker": "SIGA",
    "name": "SIGA Technologies, Inc.",
    "description": "SIGA Technologies, Inc. is a biotechnology company focused on the development and commercialization of solutions for serious infectious diseases. Founded in 1995, SIGA is committed to advancing the health of the public through its innovative therapeutics and technologies aimed at addressing unmet medical needs. The company is primarily known for its lead product, TPOXX (tecovirimat), an antiviral treatment for smallpox, which is a critical countermeasure against biological threats. SIGA's research and development efforts are centered on developing antiviral therapeutics for a range of viral infections, including those caused by orthopoxviruses and arenaviruses. With a strong dedication to public health and biodefense, SIGA works closely with government agencies and health organizations to ensure preparedness against potential outbreaks. The company also focuses on expanding its product portfolio through strategic partnerships and collaborations, thereby enhancing its capabilities to respond to emerging infectious diseases. As a leader in the biodefense sector, SIGA plays a vital role in safeguarding public health and providing innovative solutions to combat global health threats.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York, New York, USA",
    "founded": "1995",
    "website": "https://www.siga.com",
    "ceo": "Philippe Tardieu",
    "social_media": {
        "twitter": "https://twitter.com/SIGA_Technologies",
        "linkedin": "https://www.linkedin.com/company/siga-technologies-inc/"
    },
    "investor_relations": "https://investors.siga.com",
    "key_executives": [
        {
            "name": "Philippe Tardieu",
            "position": "CEO"
        },
        {
            "name": "Eric Rose",
            "position": "Co-Founder and Former CEO"
        }
    ],
    "product_categories": [
        {
            "category": "Antiviral Therapies",
            "products": [
                "TPOXX (tecovirimat)"
            ]
        }
    ],
    "seo": {
        "meta_title": "SIGA Technologies, Inc. | Biodefense and Antiviral Solutions",
        "meta_description": "Explore SIGA Technologies, Inc., a leader in biodefense and antiviral therapeutics. Learn about SIGA's innovative solutions for infectious diseases and public health.",
        "keywords": [
            "SIGA Technologies",
            "Biotechnology",
            "Antiviral Drugs",
            "Biodefense",
            "TPOXX",
            "Infectious Diseases"
        ]
    },
    "faq": [
        {
            "question": "What is SIGA Technologies known for?",
            "answer": "SIGA Technologies is known for its development of antiviral therapeutics, particularly TPOXX for the treatment of smallpox."
        },
        {
            "question": "Who is the CEO of SIGA Technologies?",
            "answer": "Philippe Tardieu is the CEO of SIGA Technologies, Inc."
        },
        {
            "question": "Where is SIGA headquartered?",
            "answer": "SIGA Technologies is headquartered in New York, New York, USA."
        },
        {
            "question": "What are SIGA's main products?",
            "answer": "SIGA's main product is TPOXX (tecovirimat), an antiviral treatment for smallpox."
        },
        {
            "question": "When was SIGA Technologies founded?",
            "answer": "SIGA Technologies was founded in 1995."
        }
    ],
    "competitors": [
        "PFE",
        "GILD",
        "AMGN",
        "MRNA"
    ],
    "related_stocks": [
        "JNJ",
        "ABBV",
        "BMY",
        "NVS"
    ]
}